london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

Posters

Choroidal thickness in branch retinal vein occlusion with macular edema

Poster Details

First Author: I.S.Byon SOUTH KOREA

Co Author(s):    M.K. Shin   S.W. Park   J.E. Lee            0   0 0   0 0   0 0   0 0

Abstract Details



Purpose:

To evaluate the change of choroidal thickness after intravitreal bevacizumab injection for branch retinal vein occlusion (BRVO) with macular edema (ME)

Setting:

Retrospective case controlled study

Methods:

A retrospective analysis was performed for unilateral BRVO patients receiving intravitreal anti-vascular endothelial growth factor (anti-VEGF, bevaciumab) for the treatment of ME. Central subfield macular thickness (CSMT) of retina, central choroidal thickness, para-central choroidal thickness of 2mm superior and inferior to fovea (choroidal thickness of the occlusive lesion and non-occlusive lesion) were obtained at baseline, 3, 6 months after bevacizumab injection using spectral domain optical coherence tomography (OCT) scan images and medical records, and were compared to fellow eye.

Results:

Of 57 eyes with BRVO and ME, mean CSMT and para-central choroidal thickness of occlusive lesion was 383 ± 182 μm and 386 ± 92 μm, which were significantly thicker than 240 ± 34 μm and 319 ± 59 μm in fellow eyes at baseline (p<0.05). The central choroidal thickness and para-central choroidal thickness of non-occlusive lesion had no significant difference between BRVO eyes and fellow eyes. Although CSMT and para-central choroidal thickness of occlusive lesion significantly decreased to 274 ± 73 μm and 349 ± 72 μm at 3 months, and 242 ± 106 μm and 356 ± 66 μm at 6 months (p<0.05), para-central choroidal thickness of occlusive lesion was significant thicker than that of non-occlusive lesion during the follow-up period (p<0.05). The central choroidal thickness and para-central choroidal thickness of non-occlusive lesion did not show the significant changes before and after bevacizumab injection.

Conclusions:

Localized retinal ischemia thickened the adjacent choroid. Anti-VEGF could reduce retinal edema as well as adjacent thickened choroid. Thick choroid may be followed by pathologic change of retina, such as increased VEGF in retinal vascular occlusive disease.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy